Quality Agreement Service Provider

A sufficiently detailed quality agreement can help to avoid assumptions leading to conformity errors. While a quality agreement defines the specific quality parameters of a project and which parties are responsible for its execution, the degree of detail varies depending on the development phase of the project. At least a quality agreement should delineate the obligations and responsibilities of each party in the following basic elements: Manufacturing quality agreements are comprehensive written agreements between parties involved in the manufacture of medicinal products and define the manufacturing activities of each party with regard to how each party will comply with the CMMs. This section should have been at the heart of the guidelines, but it consists of only two paragraphs. One of the main challenges of using a CMO is to define how the quality units of the two organizations collaborate and interact with each other. While it is true that the sponsor of the drug cannot delegate its responsibilities for cGMP compliance, the complexity of coordinating the quality management system (QMS) of a drug sponsor with that of a CMOs is palpable. For example, Person-in-the-Plant (PIP) is a relationship point where friction can arise between a CMO and a sponsor. The rights and obligations of notification, frequency, access and communication are elements that must be clearly defined in a quality agreement. A CMO has multiple clients, and each PIP requires hosting and management, thus adding an additional level of organization management to the operation of the CMO. The FDA has no specific guidelines regarding quality agreements between medical device companies and the CMOs that provide services to them. However, fda guidelines state that quality agreements should cover activities under 21 CFR Part 820, the Quality System Regulation (QSR) for medical device companies, “where applicable.” Given the inclusion of Part 820 in the Guide, a quality agreement between a medical engineering company and a CMO should address the following aspects to varying degrees, depending on the nature of the relationship between the two parties and the products and services concerned: an effective quality agreement identifies the specific sites where the contract establishment will carry out manufacturing operations. including the specific services that must be provided at each site. One element of the CMO`s commitment, which has been hotly debated in the sector, is the quality agreement which, in the new guidelines, “defines and establishes a comprehensive written agreement between the parties involved in the manufacture of medicines, which defines and defines the manufacturing activities of each party with regard to compliance with CGMP”.

As CMOs assume a much larger share of the responsibility for development – which develop in CDMs – many questions have been raised about the content and timing of quality agreements. Indeed, the value of tailor-made quality agreements has been a point of discussion. Let`s look at the FDA`s new guidelines in this context. The agreement must specify the controlled and documented changes that can only be made by the contractor with the notification of the owner and those that must be discussed, verified and approved by the owner before being implemented. Quality agreements are not only good business practices – there are also regulatory requirements for them.. . . .

Reacties zijn gesloten.